MRTX - Mirati Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
52.40
+0.90 (+1.75%)
At close: 4:00PM EDT

52.45 +0.05 (0.10%)
After hours: 5:34PM EDT

Stock chart is not supported by your current browser
Previous Close51.50
Open51.55
Bid50.35 x 2200
Ask52.50 x 800
Day's Range50.35 - 53.50
52 Week Range3.10 - 53.50
Volume399,227
Avg. Volume481,120
Market Cap1.665B
Beta2.36
PE Ratio (TTM)N/A
EPS (TTM)-2.55
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.57
Trade prices are not sourced from all markets
  • Cramer's lightning round: After Opko Health's quarter, it...
    CNBC Videos7 months ago

    Cramer's lightning round: After Opko Health's quarter, it...

    Jim Cramer sped through his take on callers' favorite stocks, including a struggling medical play.

  • Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
    PR Newswire10 days ago

    Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN DIEGO , June 11, 2018 /PRNewswire/ --   Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 3,162,500 shares of its common ...

  • Here's Why Mirati Therapeutics, Inc. Is Rising Today
    Motley Fool14 days ago

    Here's Why Mirati Therapeutics, Inc. Is Rising Today

    Wall Street cheers after the company announced favorable terms from a just-announced capital raise. Here's what investors need to know.

  • Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
    PR Newswire15 days ago

    Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

    SAN DIEGO, June 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the pricing of an underwritten public offering of 2,750,000 shares of its common stock at a price to the public of $38.85 per share. In addition, and in lieu of common stock, Mirati is offering to certain investors pre-funded warrants to purchase up to an aggregate of 421,650 shares of common stock at a purchase price of $38.849 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $123.2 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.

  • Mirati Therapeutics Announces Proposed Public Offering of Common Stock
    PR Newswire15 days ago

    Mirati Therapeutics Announces Proposed Public Offering of Common Stock

    SAN DIEGO, June 6, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares are being offered by Mirati.

  • Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting
    PR Newswire21 days ago

    Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting

    SAN DIEGO , May 31, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that new data from the ongoing Phase 1b clinical trial of single ...

  • Mirati Therapeutics To Present At Jefferies 2018 Global Healthcare Conference
    PR Newswire22 days ago

    Mirati Therapeutics To Present At Jefferies 2018 Global Healthcare Conference

    SAN DIEGO , May 30, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the Jefferies Annual Global Healthcare Conference in New York ...

  • Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session
    Zacks24 days ago

    Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session

    Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.

  • Associated Presslast month

    Mirati: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 51 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • Mirati Therapeutics Reports First Quarter Financial Results
    PR Newswirelast month

    Mirati Therapeutics Reports First Quarter Financial Results

    SAN DIEGO , May 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company, today reported financial results for the first quarter ended March 31, 2018 . "We ...

  • MarketWatch2 months ago

    Harry Boxer’s four biotech stocks to watch today

    Biotechnology stocks dominate our list of top charts to watch, with a uranium producer also advancing to the list. CASI Pharmaceuticals Inc.(CASI) rose 48 cents, or 7.2%, to $7.14 on 773,700 shares traded Tuesday. The move came on no news from the company, although the stock soared in early April on news that China’s Food and Drug Administration (CFDA) would convene a panel to discuss its cancer therapy, Evomela.

  • Can These Top-Performing Biotech Stocks Keep Climbing?
    Motley Fool2 months ago

    Can These Top-Performing Biotech Stocks Keep Climbing?

    Over the past year, these two biotech stocks outperformed nearly all their peers. Can they keep it going?

  • MarketWatch2 months ago

    Harry Boxer’s two biotechnology stocks to watch today

    In focus: Heron Therapeutics and Mirati Therapeutics.

  • Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
    PR Newswire2 months ago

    Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials

    SAN DIEGO, April 24, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) (the Company or Mirati), a clinical-stage targeted oncology company, today provided a progress update on its lead development programs and announced updated, positive clinical trial data for sitravatinib, a spectrum selective kinase inhibitor, and mocetinostat, a class I and IV HDAC inhibitor. The Company has been evaluating sitravatinib and mocetinostat in separate Phase 2 clinical trials in combination with checkpoint inhibitor therapy in non-small cell lung cancer (NSCLC) patients whose disease had progressed following prior treatment with a checkpoint inhibitor.

  • Did Mirati Therapeutics Inc’s (NASDAQ:MRTX) Recent Earnings Growth Beat The Trend?
    Simply Wall St.3 months ago

    Did Mirati Therapeutics Inc’s (NASDAQ:MRTX) Recent Earnings Growth Beat The Trend?

    Examining Mirati Therapeutics Inc’s (NASDAQ:MRTX) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, whichRead More...

  • Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results
    PR Newswire3 months ago

    Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results

    SAN DIEGO , March 8, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, today reported financial results for the fourth quarter and full-year ...

  • Mirati Therapeutics To Present At Upcoming Healthcare Conferences
    PR Newswire3 months ago

    Mirati Therapeutics To Present At Upcoming Healthcare Conferences

    SAN DIEGO , March 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at three upcoming healthcare conferences. Cowen 38 th Annual ...

  • Mirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference
    PR Newswire4 months ago

    Mirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference

    SAN DIEGO , Feb. 8, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will participate in the Leerink Partners 7 th Annual Global ...

  • Forbes5 months ago

    Nektar Notches New Highs As Stock Triples In Two Months

    Biotech and pharma stocks dominate our list of top charts to watch today.

  • Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
    PR Newswire7 months ago

    Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the closing of its previously announced underwritten public offering of 2,938,986 shares of its common stock at a public offering price of $13.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 923,085 additional shares of common stock. In addition, and in lieu of common stock, Mirati sold to certain investors pre-funded warrants to purchase up to an aggregate of 4,137,999 shares of common stock at a purchase price of $12.999 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant.  The aggregate gross proceeds to Mirati from this offering were approximately $92.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.

  • Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
    PR Newswire7 months ago

    Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

    SAN DIEGO, Nov. 16, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the pricing of an underwritten public offering of 2,015,901 shares of its common stock at a price to the public of $13.00 per share. In addition, and in lieu of common stock, Mirati is offering to certain investors pre-funded warrants to purchase up to an aggregate of 4,137,999 shares of common stock at a purchase price of $12.999 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds from this offering are expected to be approximately $80.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. Mirati has granted the underwriters a 30-day option to purchase up to an additional 923,085 shares of common stock in connection with the public offering.